Advanced searches left 3/3

Prostate Cancer - Europe PMC

Summarized by Plex Scholar
Last Updated: 24 November 2022

* If you want to update the article please login/register

Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea.

We compared the FoundationOne CDx and other NGS assays with samples from the PROfound trial in Korea as locally adopted multigene panel next-generation sequencing assays for selecting PARP inhibitor candidates have not been thoroughly reviewed. The results of HRR gene mutation analysis were compared between the FoundationOne CDx and two other NGS assays [SureSelect Custom Design assay and Oncomine Comprehensive assay]. The OPA for copy number variants of the Oncomine Comprehensive and SureSelect Custom assays increased by 99. 8%-100%, relative to that of the FoundationOne CDx assay. Conclusions The NGS approach at a local laboratory yielded similar analytical results in determining HRRm status to the FoundationOne CDx assay used at the central laboratory.

Source link: https://europepmc.org/article/MED/36045058


The effects of resistance exercise on body composition and physical function in prostate cancer patients undergoing androgen deprivation therapy: an update systematic review and meta-analysis.

Objectives The aim of the meta-analysis was to determine the effects of resistance exercise on body composition and physical function in patients with prostate cancer. Key findings These studies revealed significant improvements in body composition and physical fitness. According to subgroup results, RE for u2265 6 months and starting exercise immediately after androgen deprivation therapy resulted in more significant changes in body composition. In addition, the results revealed that the exercise intensity of 8-12 RM had a significant effect on body composition. Conclusions RE seems to be a promising strategy in order to enhance body composition and physical function in PCa patients in order to minimize their treatment-related side effects. Rere should be used as a means of recovery and care for PCa. Starting exercise immediately after ADT and extending exercise time when choosing the right intensity will help improve the patients' body composition and function.

Source link: https://europepmc.org/article/MED/36382930


Cardiometabolic side effects of androgen deprivation therapy in prostate cancer.

Purpose of investigation Androgen-deprivation therapy is widely used for the treatment of advanced prostate cancer, and it is considered the frontline therapy. In this review, we look at the literature on ADT's cardiovascular effects and the physiologic mechanisms underpinning CVD's relationship. Patients receiving GnRH antagonist therapy will have a different course in major cardiovascular events among GnRH agonist-treated patients compared to those with GnRH antagonist therapy. We will also address the important differences in major cardiovascular events among GnRH agonist-treated patients, as well as patients undergoing GnRH antagonist therapy. GnRH agonists may be at a greater risk of cardiovascular disease and morbidity than GnRH antagonists, but this relationship is yet to be established. In addition, testing for cardiovascular risk factors before and during ADT therapy is a vital step in preventing major adverse cardiac events in prostate cancer patients. Summary ADT is a very effective treatment option for advanced prostate cancer that improves survival rates while also increasing patient cardiovascular health, which has the potential of greatly affecting patients' cardiovascular health.

Source link: https://europepmc.org/article/MED/36349380


Suppressive function of bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-187 in prostate cancer.

Bone marrow-derived mesenchymal stem cell-derived exosomes have been used in cancer therapy for a long time. We've outlined here how microRNA-187, a microRNA-187 gene in prostate cancer, plays an important role. In prostate cancer, the relationship between CD276 and miR-187 was investigated. Their role in prostate cancer cell biological processes was determined by miR-187 mimic/inhibitor or CD276 overexpression transfection transfection. For determining the in vitro and in vivo effects of exosomal miR-187, prostate cancer cells were then exposed to BMSC-exos that were either miR-187 mimic/inhibitor or CD276 overexpression. In addition, miR-187 restored miR-187 inhibited prostate cancer cell malignant functions by attacking CD276.

Source link: https://europepmc.org/article/MED/36245088


Sasanquasaponin inhibited epithelial to mesenchymal transition in prostate cancer by regulating the PI3K/Akt/mTOR and Smad pathways.

Context Sasanquasaponin, a commonly used traditional Chinese medicine, has a variety of medicinal functions and has a wide variety of health effects. Object The aim of this research is to determine the effect and underlying mechanism of SQS in prostate cancer treatment. Cell lines were treated with SQS for 12 or 24 hours, and the mRNA and protein levels of epithelial to mesenchymal transition -related genes in PC cell lines were determined. The migration and invasion capabilities of PC cell lines were tested. SQS antitumour activity in BALB/c nude mice was also investigated, eventually. In the process of EMT, the PI3K/Akt/mTOR and Smad2/3 signalling pathways were ignited, and SQS could significantly reduce the initiation of the PI3K/Akt/mTOR and Smad2/3 pathways, as shown by EMT. SQS inhibited EMT in PC by governing the PI3K/Akt/mTOR and Smad pathways.

Source link: https://europepmc.org/article/MED/36205544


Feasibility of assessing male osteoporosis using MRI IDEAL-IQ sequence of proximal femur in prostate cancer patients.

A new method for quantifying iron and fat content by MRI IDEAL-IQ can map hematopoietic regions and fatty deposits in bone marrow; however, the relationship between these indices and total hip bone mineral density remains uncertain. The proximal femur of 104 men who underwent pelvic MRI and bone densitometry prior to diagnosis of non-metastatic prostate cancer treatment was retrospectively examined to determine the R2* value to determine bone marrow fat fractions.

Source link: https://europepmc.org/article/MED/35997228


Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.

Prostate cancer is the most common malignant tumor in men. On the surface of PCa cells, a prostate-specific membrane antigen is overexpressed. This research sought to develop a PSMA-targeted, glutathione-sensitive, DTX and EZL co-loaded nanoparticles to treat PCa. Polyethylene glycol was conjugated with oleic acid using a GSH-sensitive ligand, cystamine. Human prostate cancer cell lines and PCa cells bearing mice were used to determine the system's in vitro and in vivo effectiveness, as well as in vivo and in vivo functionality. About 70% uptake in GC-SS DTX/EZL-NPs, as well as improved cell growth inhibition capacity than single drug-loaded NPs and free drugs, was seen in comparison to single drug-loaded NPs and free medications. The most effective tumor inhibiting ability and less systemic toxicity were demonstrated by GUL-SS DTX/EZL-NPs, which also reduced systemic toxicity. The novel GUL-SS DTX/EZL-NPs could be used as a promising device for PCa therapy.

Source link: https://europepmc.org/article/MED/35980107


Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study.

In the national cohort of patients diagnosed with prostate cancer and treated with ADT, ADT patients were less likely to die in CVD than non-users compared with ADT non-users. Methods and methods: Using the Lithuanian Cancer registry results, we conducted a retrospective cohort study of patients aged 40-79 years and diagnosed with prostate cancer between January 2012 and December 2016. In the final study cohort that exclusively used gonadotropin-releasing hormone agonists, 13 343 prostate cancer patients were included. ADT users with ADT had a higher risk of CVD deaths in the cohort of patients treated with ADT than ADT non-users. Also, among ADT users, there was an elevated risk of death from ischemic heart disease and stroke. Conclusions: This report found that ADT use is associated with elevated CVD-related mortality risk for patients diagnosed with prostate cancer in comparison to ADT non-users.

Source link: https://europepmc.org/article/MED/35882633


Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients.

Weight change was remarkably related to log loss, and the longer the PSADT, according to Linear regression studies, the longer the log was longer. Nevertheless, the mediation report found that zonulin was not a significant intermediary mechanism for the effect of weight change on PSADT. Conclusions: Future studies are highly recommended to investigate the potential correlation of IP with inflammation and to determine if change in IP is related to reduced PC progression. As indicated by the PSA's doubling time, intestinal microbiota can influence prostate cancer, prostate cancer, and perhaps indirectly by affecting intestinal permeability in prostate cancer patients.

Source link: https://europepmc.org/article/MED/35486445


Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.

Despite the success of androgen deprivation therapy in advanced prostate cancer, severe neuropsychiatric complications in androgen deprivation therapy-treated patients, mainly depression, have been troubling and have drew more concern lately. The ADT-treated patients' mean average was 18. 23%, compared to 8. 42% in the non-ADT patients, based on the incidence of depression found by the observational studies. Some research has been published on the other hand, a few experimental studies have been published into the safety of selective serotonin reuptake inhibitors, selective serotonin and nominone reuptake inhibitors, and/or saftey on other ADT-related adverse effects. The foundation that can be used to test these drugs on ADT-induced depression was established by clinical trials published about the use of antidepressants for other ADT-related adverse effects.

Source link: https://europepmc.org/article/MED/35343371

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions